RSS

GBI Research

Rapid growth from $1.64 billion in 2017 to $6.07 billion in 2024 is expected in the global orphan and rare dermatology premium products market, according to business intelligence provider, GBI Research. more

Analysis

Fewer than two in 10 medicines exceed the average pharmaceutical R&D cost required to bring a drug to market when the risks of failure to reach market approval are factored in, according to GBI Research. more

News

According to a recent report from business intelligence provider, GBI Research, the pharmaceutical industry is seeking new business models. more

News

The latest report by business intelligence provider GBI research shows that new opportunities for biosimilar manufacturers are being presented through patent expiries of key biologics. more

News

According to business intelligence provider GBI Research, pharmaceuticals company Roche will be the biggest mover in the neurodegenerative drugs space over the next five years. more

News

A recent report from market analyst group GBI Research has revealed the extent to which organisations in the pharmaceutical and healthcare industry are planning to invest in big data. more

News

A recent report by business intelligence provider GBI Research suggests that the antibacterial drugs market is set to reach $35.6 billion by 2022. more

News

Analyst company GBI Research has concluded that due to an increasing demand for type 2 diabetes mellitus (T2DM) therapeutics, there is a large and competitive market landscape. more

News

Despite it costing £1.8bn ($2.6bn) to bring a novel drug to market, pharmaceutical companies are increasingly looking towards developing first-in-class treatments to maximise revenue and stay ahead of competition, according to GBI Research more

News

Vets are prescribing drugs intended for human use to animals, according to a report by business intelligence provider GBI Research more

News

The treatment market for pancreatic cancer is set to grow from its current level of £1.2bn ($1.9bn) to an impressive £1.9bn ($2.9bn) by 2021 more

News

With the average cost of getting a novel drug to market at almost £1.6bn ($2.5bn) deal-making is becoming vital for pharmaceutical companies to offset rising Research and Development (R&D) costs, according to GBI Research more

News

A rising diabetes rate will lead the Southeast Asian glucose monitoring devices market more than double from $130.4 million to $267 million by 2020. more